Hydroxychloroquine trial suspended by WHO

Amy Baxter | | Health Exec | Management

The World Health Organization has suspended the trial of the controversial drug hydroxychloroquine due to safety concerns, Axios reported. The report comes just a few weeks after President Trump announced he had been taking the drug as a preventative measure against infection of COVID-19.

Hydroxychloroquine has been touted by Trump as a treatment for COVID-19, though evidence that the drug, which is typically used to treat malaria, is effective against COVID-19 has not been proven. The FDA has also issued a warning that the drug should only be administered in hospitals due to the heart risks.

WHO decided to shut down its trial of the drug as a COVID-19 treatment after patients who took it were more likely to die or develop irregular heart rhythm and potentially sudden cardiac death than those who did nothing. Those findings were recently published in The Lancet, which reviewed 96,000 hospitalized COVID-19 patients in six continents between Dec. 20, 2019 and April 14, 2020.

See the full story below:

WHO temporarily suspends trial of hydroxychloroquine over safety concerns

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Boston Medical Center installs solar panels to pay patients’ electric bills
FDA recalls infant incubators due to risk of door falling off
Private equity firm to buy medical software company for $1.1B
Stewardship Health sale to private equity finalized for $245M
Baxter producing IV solutions ahead of schedule at Asheville-area site
Hackers were inside an Iowa hospital’s network for two weeks

Around the web

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Design by Adaptive Theme
Trimed Popup
Trimed Popup